Transdermal Drug Delivery System for Atomoxetine Hydrochloride – In vitro and Ex vivo Evaluation

Order of Publishing in Issue: 
9
Volume :3
Issue :2
April, 2009
Page No: 
188-196
Authors: 
Mamatha T1, Venkateswara Rao J1*, Mukkanti K2 and Ramesh G3
Address: 
1Sultan–Ul–Uloom College of Pharmacy, Road No.3, Banjarahills, Hyderabad-500034, (A.P.), India
Address: 
2Centre for Environment, Jawaharlal Nehru Technological University, Kukatpally Hyderabad-500072 (A.P.), India
Address: 
3Centre for Biopharmaceutics and Pharmacokinetics, University College of Pharmaceutical Sciences Kakatiya University, Warangal- 506 009 (A.P.), India
Email-ID: 
jvrao1963@yahoo.co.in

Abstract:
Monolithic matrix type transdermal drugdelivery systems (TDDS) of atomoxetinehydrochloride (A-HCl) were prepared by the filmcasting on a mercury substrate and characterizedby physicochemical characteristics like thickness,weight variation, drug content, flatness, foldingendurance and in vitro drug release studies, exvivo skin permeation studies. Eight formulations(carrying Eudragit RL100 and Hydroxypropylmethyl cellulose 15 cps in the ratios of 8:2, 6:4,4:6, 2:8 in formulations A-1, A-2, A-3, A-4 andEudragit RS 100 and Hydroxypropyl methylcellulose 15 cps in the same ratios in formulationsB-1, B-2, B-3, B-4 respectively) were prepared.All formulations carried 20 mg of drug, A-HCl,10% w/w of propylene glycol as penetrationenhancer, 10% w/w of dibutyl phthalate asplasticizer in ethanol. The formulations exhibiteduniform thickness, weight and good uniformity indrug content. The maximum drug release in 24hrs for A-series formulations was 95.52 % (A-3) and for B-series, it was 89.55 % (B-4). Againformulations A-3 (Kp = 3.53 X 10-2 cm h-1) andB-4 (Kp = 3.20 X 10-2 cm h-1) exhibited the bestskin permeation potential in the respective series.On the basis of in vitro drug release and ex vivoskin permeation performance, formulation A-3was found to be better than the other sevenformulations. The results of the study show thatA-HCl could be administered transdermally
through the matrix type TDDS for effectivecontrol of attention-deficit/hyperactivity disorder(ADHD) in children, adolescents, and adults.

Keywords: 
Transdermal, atomoxetine hydrochloride, propylene glycol, Eudragit, HPMC.
AttachmentSize
Paper-9.pdf84.84 KB

 
To download full text articles and issues in PDF at no cost.All you have to do is fill out a brief registration form. It's easy and it's free. At any time, you may request removal of your contact information from our database.
Click here to Register | Click here if you have already registered

2018 ABAP Awards

Invitation for Nominations to 2019 ABAP Awards
The Association of Biotechnology and Pharmacy invites nominations for the following awards from the eligible talented people with proven track record and achievements on or before August 31, 2019 in the prescribed format.

DOWNLOAD CIRCULAR | APPLICATION FORM

AWARDS

User login